Abstract:Background: Impairment of the NO/cGMP pathway accelerates ischemia/reperfusion injury following lung transplantation (LTPL). Direct application of NO is not ideal because of its short half-life and toxic side effects. Tetrahydrobiopterin (BH4) is the essential coenzyme of the NO synthase. 8-Br-cGMP is a membrane permeable analogue of cGMP, second messenger of NO. We evaluated the effect and several treatment modalities with these compounds on post-transplant lung ischemia/reperfusion injury in a large animal model. Methods: Unilateral left LTPL was performed in 25 weight matched outbred pigs (all groups n = 5). Donor lungs were flushed with 1.5 1 cold LPD solution and preserved for 20 h at 1 degrees C. In group I and II recipients were treated with a bolus of BH4 (20 mg/kg) over 30 min, starting 15 min before reperfusion. In group II an additional continuous dose of BH4 (10 mg/kg) was given over the entire observation period. In group III 8-Br-cGMP (1 mg/kg) was added to the flush solution and in group IV 8-Br-cGMP was given as continuous infusion (0.2 mg/kg/h) over 5 h starting 15 min before reperfusion. Group V served as control. All donors (except group III) received 250 mu g PGE1 injected into the pulmonary artery prior to flush. One hour after reperfusion the recipient contralateral right pulmonary artery and bronchus were ligated to assess graft function only. Extravascular lung water index (EVLWI) and hemodynamic parameters (PAP, PVR, CO) were assessed during a five hour observation period. Lipid peroxidation (TBARS) and neutrophil migration to the allograft (MPO activity) were measured at the end of the assessment. cGMP levels were determined in the pulmonary venous and arterial blood in all animals. Results: EVLWI (2 h after reperfusion), MPG, TBARS and cGMP at the end of the assessment are summarized below. [GRAPHICS] No effect on pulmonary and systemic hemodynamic parameters with either treatment could be detected. Conclusions: Our results show that substitution of the NO pathway by BH4 or 8-Br-cGMP respectively reduces post-transplant pulmonary edema, neutrophil migration, and lipid peroxidation in the allograft. Addition of 8-Br-cGMP to the flush solution is superior to PGE1. Based on pharmacologic considerations of both substances and the presented results, administration of cGMP in the flush solution and BH4 during reperfusion seems to be very promising.

In vivo lung perfusion for prompt recovery from primary graft dysfunction after lung transplantation

The Conversional Efficacy of Ex Vivo Lung Perfusion and Clinical Outcomes in Patients Undergoing Transplantation of Donor Lungs by Ex Vivo Lung Perfusion: A Meta-Analysis.

Ex Vivo Lung Perfusion and Primary Graft Dysfunction Following Lung Transplantation: A Contemporary United Network for Organ Sharing Database Analysis

Prevention and Treatment of Primary Graft Dysfunction after Lung Transplantation (108 Cases Report)

Inhalative pre-treatment of donor lungs using the aerosolized prostacyclin analog iloprost ameliorates reperfusion injury

Perfusate adsorption during ex vivo lung perfusion improves early post-transplant lung function

New strategies to reduce ischemia/reperfusion injury following lung allotransplantation by substitution of the NO/cGMP pathway

A New Way Forward to Expand the Donor Pool

Histologic and functional evaluation of lungs reconditioned by ex vivo lung perfusion

Cost-effective Donor Lung Preservation with High-Volume Continuous Perfusate Purification in Ex Vivo Lung Perfusion

Argon and xenon ventilation during prolonged ex vivo lung perfusion

Liquid Ventilation Reconditions Isolated Rat Lungs Following Ischemia-Reperfusion Injury

Ex vivo lung perfusion with perfusate purification for human donor lungs following prolonged cold storage

Reduction of primary graft dysfunction using cytokine adsorption during organ preservation and after lung transplantation

Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation

Ex vivo MFG-E8 treatment improves the function of lungs procured from cardiac death donors in preclinical porcine model

Clinical analysis of risk factors for early primary graft dysfunction after lung transplantation

Therapeutic reconditioning of damaged lungs by transient heat stress during ex vivo lung perfusion

Clinical analysis of extracorporeal membrane oxygenation institution for primary graft dysfunction after lung transplantation

The impact of ex vivo lung perfusion location on lung transplant outcomes

Transplantation of initially rejected donor lungs after ex vivo lung perfusion